SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-008568
Filing Date
2022-05-12
Accepted
2022-05-12 16:26:35
Documents
64
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sgtx-20220331x10q.htm   iXBRL 10-Q 1628870
2 EX-31.1 sgtx-20220331xex31d1.htm EX-31.1 36596
3 EX-31.2 sgtx-20220331xex31d2.htm EX-31.2 36606
4 EX-32.1 sgtx-20220331xex32d1.htm EX-32.1 15210
  Complete submission text file 0001558370-22-008568.txt   6264640

Data Files

Seq Description Document Type Size
5 EX-101.SCH sgtx-20220331.xsd EX-101.SCH 39661
6 EX-101.CAL sgtx-20220331_cal.xml EX-101.CAL 50852
7 EX-101.DEF sgtx-20220331_def.xml EX-101.DEF 131458
8 EX-101.LAB sgtx-20220331_lab.xml EX-101.LAB 391407
9 EX-101.PRE sgtx-20220331_pre.xml EX-101.PRE 276187
58 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20220331x10q_htm.xml XML 1013637
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39746 | Film No.: 22918245
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences